


CLAIMS

1. Use of a compound having the following formula (I):



wherein:

- 5 n is 0 or an integer comprised between 1 and 5;
R is a group $R_2-X-C(=Z)-NH-$, in which X represents a simple chemical bond, an aromatic or heteroaromatic radical, Z represents an oxygen atom or the NH group;

and:

- 10 if X is a simple chemical bond, R_2 is an oxygen atom, an alkyl, dialkylaminoalkyl, alkenyl, cycloalkyl, arylalkyl, arylalkenyl, haloalkyl, or an aromatic or heteroaromatic radical;

if X is an aromatic or heteroaromatic radical, R_2 is nitro, amino or formylamino;

or:

- 15 R is a group $R_3-C(=Z)-$, in which Z represents an oxygen atom or the NH group, and R_3 represents a hydrogen atom, the $-OR_4$ or $-NR_5R_6$ group, and where:

R_4 is chosen from the group consisting of a hydrogen atom, an alkyl, cycloalkyl, arylalkyl, or an aromatic radical;

- 20 R_5 and R_6 , either the same or different, are chosen from the group consisting of a hydrogen atom, an alkyl, cycloalkyl, arylalkyl, aromatic or

heterocyclic radical, optionally substituted with a formylamino or a carbamoyl group; or

R₅ and R₆, joined together form an alkylene group, or the group -(CH₂)₂-O-(CH₂)₂- or the group -(CH₂)₂-NH-(CH₂)₂-;

5 A represents a simple chemical bond or the group -CO-NH-Y-, wherein Y is an alkylene or aromatic radical;

R₁ is chosen from the group consisting of -COOR₄, -B-NR₅R₆, -C(=NH)-NH₂, a heterocyclic radical containing nitrogen, wherein:

10 R₄, R₅ and R₆ are as defined above, B represents a simple chemical bond or the -C=O group, and:

when R₁ is -B-NR₅R₆, and B is a simple chemical bond, or when R₁ is a heterocyclic radical, A is not a chemical bond;

or a pharmaceutical acceptable salt thereof in the manufacture of a pharmaceutical composition having activity against endoparasitosis in animals.

15 2. Use according to Claim 1, where the compound of formula (I) is chosen between distamycin and a compound of formula (I) wherein:

n is as previously defined;

R is the -CONH₂ group, A is the -CONHCH₂CH₂- group, R₁ is the -C(=NH)-NH₂ group or the -CH₂N(CH₃)₂ group;

20 R is the -NH-CH(=NH) group, A is the -CONHCH₂CH₂- group, R₁ is the -C(=NH)-NH₂ group or the -CH₂N(CH₃)₂ group or the -CONH₂ group;

and the pharmaceutically acceptable salts thereof.

3. Use according to Claim 1, where the pharmaceutical composition is for oral use.


4. Use according to Claim 1, where the pharmaceutical composition is for the prophylaxis and/or treatment of endoparasitosis in animals.

25

5. Use according to Claim 4, where the endoparasitosis is chosen from Trichomoniasis, Giardiasis, Istomoniasis, Amoebiasis, Coccidiosis, and Balantidiosis.
6. Use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in association or combination with a cyclodextrin in the manufacture of a veterinary pharmaceutical composition having activity against endoparasitosis in animals.
- 5 7. Use according to Claim 6, where the pharmaceutical composition is for oral use.
8. Use according to Claim 6, where the pharmaceutical composition is for the prophylaxis and/or treatment of endoparasitosis in animals.

Title: USE OF POLY-AMMINOPYRROLECARBOXAMIDES ALONE OR IN COMBINATION WITH A CYCLODEXTRIN IN THE PROPHYLAXIS AND TREATMENT OF ANIMAL PARASITOSIS

5



I

Abstract:

10

Use of distamycin, analogues and/or derivatives thereof in the manufacture of a pharmaceutical composition having activity against endoparasitosis in animals.